Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › KS › Lenexa › NPI 1609812445
Lab

Labone LLC

Labone LLC was paid $212.28M by Medicaid between Jan 2018 and Dec 2024, across 473 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 7.4% of everything it billed.

33Billing provider infoLABONE LLC
LENEXA, KS 66219
33aNPI1609812445assigned 06/21/2006
33bProvider typeClinical Medical Laboratory
28Total paid$212.28M
24GClaims15,295,177
24DCodes billed473
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in Kansas

Rank by total paid#1 of 47
Median peer was paid$64K
This provider vs. median3,326×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official TIMMERMAN, LEAH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$2.0M$4.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20181,668,666$23.56M
20191,823,986$25.65M
20201,737,626$28.19M
20212,307,149$33.83M
20222,662,020$37.00M
20232,817,944$36.04M
2024incomplete2,277,786$27.99M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 7.4% 213,595 179,756 $15.71M
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 5.8% 430,570 401,539 $12.34M
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 5.8% 417,643 388,830 $12.24M
80050 General health panel 4.8% 264,445 253,735 $10.18M
80061 Lipid panel 4.1% 871,734 839,054 $8.78M
84443 Thyroid stimulating hormone (TSH) 3.9% 695,070 668,654 $8.31M
80053 Comprehensive metabolic panel 3.9% 1,084,491 1,023,640 $8.24M
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 3.8% 352,351 339,445 $7.99M
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 3.0% 297,186 284,395 $6.35M
85025 Blood count; complete (CBC), automated, and automated differential WBC count 2.4% 964,183 901,476 $5.11M
83036 Hemoglobin; glycosylated (A1C) 2.4% 631,935 608,986 $5.00M
80081 2.2% 79,365 76,604 $4.66M
461 more codes
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 2.1% 123,951 $4.55M
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 2.0% 174,887 $4.33M
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms 2.0% 95,155 $4.30M
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel 1.7% 7,958 $3.70M
86803 1.4% 259,267 $3.03M
81513 1.4% 40,769 $2.98M
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 1.3% 60,764 $2.80M
86003 1.2% 50,587 $2.63M
86480 1.1% 46,148 $2.35M
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 1.1% 93,802 $2.28M
87086 Culture, bacterial; quantitative colony count, urine <1% 368,988 $2.12M
82607 <1% 181,226 $2.08M
82728 <1% 179,955 $1.99M
80074 <1% 49,628 $1.89M
84439 <1% 264,816 $1.89M
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer <1% 115,505 $1.87M
83013 <1% 33,958 $1.82M
87088 <1% 257,533 $1.57M
87536 <1% 23,356 $1.50M
83655 <1% 144,441 $1.38M
87522 Neg quan hep c or qual rna <1% 40,243 $1.30M
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 59,244 $1.26M
87340 <1% 124,303 $1.26M
82746 <1% 107,566 $1.25M
83550 <1% 163,878 $1.12M
83970 <1% 36,140 $1.02M
84153 <1% 69,014 $989K
85027 <1% 210,712 $988K
84481 <1% 70,779 $935K
87799 <1% 34,337 $914K
83540 <1% 177,023 $901K
86592 <1% 249,124 $886K
84702 <1% 84,285 $884K
80048 Basic metabolic panel (calcium, ionized) <1% 138,653 $880K
87070 <1% 143,631 $872K
86235 <1% 16,133 $860K
84403 <1% 45,268 $830K
82670 <1% 36,888 $781K
86038 <1% 74,293 $768K
83001 <1% 50,440 $768K
87902 <1% 4,915 $748K
82570 <1% 181,473 $721K
87186 <1% 124,703 $666K
84146 <1% 44,705 $666K
87081 <1% 134,243 $654K
86696 <1% 38,746 $645K
82043 <1% 146,455 $635K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 11,875 $631K
87077 <1% 114,973 $629K
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants <1% 1,825 $601K
83880 <1% 25,239 $576K
87660 <1% 34,038 $560K
87480 <1% 34,108 $547K
87510 <1% 33,465 $539K
86704 <1% 51,338 $523K
83002 <1% 35,342 $492K
87150 <1% 17,889 $473K
86708 <1% 45,991 $469K
84144 <1% 30,677 $467K
86706 <1% 50,458 $446K
80055 <1% 14,613 $446K
86140 <1% 111,294 $443K
82105 <1% 27,645 $438K
84436 <1% 71,708 $401K
86695 <1% 36,635 $391K
86787 <1% 35,132 $384K
87512 <1% 15,686 $357K
82950 <1% 87,135 $349K
86376 <1% 29,913 $347K
83735 <1% 75,910 $346K
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 2,485 $339K
82677 <1% 13,634 $336K
86665 <1% 12,715 $333K
84480 <1% 29,222 $321K
81001 <1% 141,257 $318K
84479 <1% 54,396 $307K
86200 <1% 30,008 $305K
82784 <1% 29,626 $305K
82785 <1% 23,831 $304K
82627 <1% 16,369 $294K
86317 <1% 23,097 $286K
88141 <1% 21,299 $274K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 4,033 $272K
84402 <1% 16,207 $269K
86364 <1% 12,139 $269K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 6,872 $266K
80164 <1% 30,582 $250K
86800 <1% 18,021 $249K
81511 <1% 4,923 $249K
86431 <1% 51,494 $243K
88142 <1% 19,934 $242K
82378 <1% 13,491 $238K
86008 <1% 4,139 $236K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 2,231 $232K
36415 Collection of venous blood by venipuncture <1% 326,630 $224K
80076 <1% 34,027 $224K
83525 <1% 25,072 $222K
86769 <1% 6,386 $220K
83690 <1% 38,538 $215K
86336 <1% 13,640 $210K
85652 <1% 94,276 $207K
82533 <1% 14,299 $199K
86160 <1% 11,901 $195K
99001 <1% 3,978 $191K
86870 <1% 6,186 $189K
84550 <1% 54,544 $187K
86850 <1% 32,579 $182K
82951 <1% 18,233 $180K
80069 <1% 28,656 $179K
86762 <1% 16,381 $179K
87147 <1% 42,391 $173K
86300 <1% 8,579 $172K
86780 <1% 16,116 $164K
85610 <1% 51,500 $158K
86225 <1% 13,424 $155K
86039 <1% 17,329 $150K
86664 <1% 11,530 $149K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 576 $146K
87209 <1% 8,624 $140K
84460 <1% 30,806 $136K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 3,592 $130K
84681 <1% 7,990 $130K
80178 <1% 27,124 $130K
82248 <1% 34,010 $129K
83520 <1% 12,406 $128K
84156 <1% 48,769 $127K
84165 <1% 15,041 $124K
82150 <1% 22,211 $123K
82550 <1% 22,625 $116K
87255 <1% 4,555 $115K
86361 <1% 7,561 $115K
80361 <1% 7,134 $108K
84270 <1% 6,965 $107K
83014 <1% 13,733 $101K
83516 <1% 12,697 $100K
82947 <1% 29,374 $100K
83615 <1% 21,611 $99K
83721 <1% 13,517 $98K
86901 <1% 23,483 $97K
84425 <1% 6,846 $97K
85018 <1% 53,829 $95K
84450 <1% 22,297 $95K
87075 <1% 15,272 $93K
86334 <1% 5,997 $92K
85060 <1% 6,252 $90K
84703 <1% 15,097 $89K
82652 <1% 4,941 $89K
86765 <1% 9,510 $89K
84100 <1% 27,536 $87K
86304 <1% 4,885 $87K
82977 <1% 14,908 $86K
83521 <1% 3,160 $84K
86147 <1% 3,720 $81K
87529 <1% 3,253 $80K
84154 <1% 5,572 $78K
86146 <1% 3,402 $78K
87205 <1% 25,442 $77K
87427 <1% 8,572 $77K
87517 <1% 2,422 $77K
85730 <1% 15,795 $76K
80197 <1% 10,893 $76K
80349 <1% 5,992 $74K
86709 <1% 6,856 $72K
87045 <1% 8,885 $71K
86141 <1% 8,018 $71K
86757 <1% 2,882 $70K
87493 <1% 2,657 $70K
83090 <1% 5,659 $69K
80365 <1% 5,680 $69K
80346 <1% 4,606 $67K
85014 <1% 37,342 $67K
87177 <1% 8,615 $66K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 523 $66K
86735 <1% 6,137 $65K
86618 <1% 4,883 $65K
86481 <1% 1,174 $65K
86705 <1% 6,296 $65K
83020 <1% 7,183 $64K
87625 <1% 2,451 $64K
82274 <1% 6,436 $64K
82140 <1% 6,756 $63K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 2,775 $61K
87563 <1% 2,870 $60K
83718 <1% 7,499 $60K
86258 <1% 1,865 $60K
82672 <1% 3,513 $58K
84445 <1% 1,641 $57K
87449 <1% 6,813 $57K
86900 <1% 23,461 $57K
86359 <1% 2,129 $54K
82952 <1% 15,306 $50K
87481 <1% 2,784 $49K
83498 <1% 2,751 $49K
86301 <1% 2,530 $49K
82465 <1% 11,432 $48K
87329 <1% 5,289 $47K
80362 <1% 4,187 $46K
82565 <1% 13,298 $46K
82330 <1% 4,340 $46K
80348 <1% 3,859 $46K
86593 <1% 13,032 $45K
82024 <1% 2,246 $45K
82247 <1% 12,130 $44K
82310 <1% 11,446 $42K
83021 <1% 3,252 $42K
87800 <1% 3,157 $42K
82542 <1% 3,753 $42K
81512 <1% 1,054 $40K
80156 <1% 4,541 $39K
81596 <1% 2,271 $38K
80177 <1% 4,833 $37K
83993 <1% 2,581 $37K
85379 <1% 4,927 $37K
81003 <1% 20,225 $37K
80369 <1% 2,744 $37K
85045 <1% 11,321 $37K
84466 <1% 3,505 $35K
85660 <1% 8,212 $35K
86645 <1% 2,684 $35K
86162 <1% 2,155 $35K
80373 <1% 2,857 $34K
86644 <1% 2,887 $33K
80324 <1% 2,889 $33K
87901 <1% 205 $32K
86666 <1% 4,882 $32K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 1,508 $32K
80185 <1% 4,021 $32K
84155 <1% 12,477 $31K
82040 <1% 8,158 $31K
84134 <1% 3,736 $31K
80358 <1% 2,759 $31K
86360 <1% 1,169 $30K
88342 <1% 636 $30K
80355 <1% 2,604 $30K
81025 <1% 5,394 $30K
86255 <1% 3,974 $30K
80323 <1% 1,902 $30K
86060 <1% 3,979 $29K
82103 <1% 2,655 $29K
84305 <1% 1,970 $28K
86707 <1% 2,483 $27K
82390 <1% 3,173 $27K
83010 <1% 2,932 $27K
86355 <1% 882 $26K
85007 <1% 11,027 $26K
82668 <1% 1,743 $26K
80368 <1% 2,358 $25K
81329 <1% 361 $25K
82088 <1% 1,010 $25K
86308 <1% 5,446 $25K
86341 <1% 1,286 $25K
84166 <1% 2,039 $24K
85246 <1% 1,359 $24K
84432 <1% 1,985 $24K
86357 <1% 749 $23K
84075 <1% 5,865 $23K
87338 <1% 2,922 $22K
86021 <1% 2,439 $22K
84207 <1% 1,471 $22K
87324 <1% 2,468 $22K
80360 <1% 1,967 $22K
87102 <1% 3,182 $21K
85245 <1% 1,192 $21K
83704 <1% 1,869 $21K
86617 <1% 1,078 $21K
85004 <1% 4,710 $21K
85240 <1% 1,412 $20K
86381 <1% 1,025 $20K
80372 <1% 1,832 $20K
85041 <1% 9,043 $20K
84478 <1% 4,998 $20K
84630 <1% 2,769 $20K
84446 <1% 1,674 $20K
81015 <1% 8,335 $19K
80366 <1% 1,747 $19K
84590 <1% 2,132 $18K
87046 <1% 4,123 $18K
87900 <1% 223 $18K
86886 <1% 3,876 $18K
86753 <1% 1,748 $18K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 1,708 $18K
80359 <1% 1,757 $17K
80175 <1% 2,354 $17K
84484 <1% 2,497 $17K
86880 <1% 2,358 $17K
82747 <1% 1,355 $16K
86036 <1% 1,114 $16K
83921 <1% 1,744 $16K
84597 <1% 1,259 $16K
83992 <1% 1,589 $16K
82164 <1% 1,561 $16K
87076 <1% 2,514 $16K
84520 <1% 6,118 $16K
83883 <1% 2,340 $15K
87040 <1% 2,458 $15K
81241 <1% 357 $14K
82653 <1% 404 $14K
84244 <1% 1,014 $14K
86812 <1% 778 $14K
86777 <1% 1,283 $14K
82232 <1% 1,019 $14K
86015 <1% 1,179 $14K
81443 <1% 14 $14K
87101 <1% 2,821 $14K
82397 <1% 1,261 $13K
85613 <1% 2,247 $13K
80354 <1% 1,318 $13K
82172 <1% 1,724 $13K
80374 <1% 1,219 $12K
80159 <1% 1,541 $12K
82085 <1% 1,806 $12K
85048 <1% 6,387 $12K
84132 <1% 3,402 $12K
87650 <1% 987 $12K
82610 <1% 950 $12K
87497 <1% 861 $12K
82671 <1% 576 $11K
83698 <1% 1,103 $11K
80371 <1% 791 $11K
84482 <1% 1,337 $11K
86231 <1% 523 $11K
87328 <1% 1,189 $11K
80183 <1% 1,343 $11K
84182 <1% 175 $11K
87350 <1% 1,093 $10K
80321 <1% 1,019 $10K
80338 <1% 813 $10K
84295 <1% 2,749 $10K
85247 <1% 519 $10K
82679 <1% 640 $10K
87106 <1% 1,276 $9K
82626 <1% 567 $9K
80345 <1% 1,218 $9K
85049 <1% 2,828 $9K
80051 <1% 2,000 $9K
86682 <1% 969 $9K
82525 <1% 1,083 $9K
83695 <1% 1,632 $9K
86702 <1% 794 $8K
80332 <1% 634 $8K
83935 <1% 1,636 $8K
87107 <1% 824 $8K
87140 <1% 1,460 $8K
86337 <1% 461 $8K
88304 <1% 276 $8K
86778 <1% 633 $7K
87206 <1% 2,036 $7K
82530 <1% 747 $7K
80356 <1% 730 $7K
80337 <1% 517 $7K
85306 <1% 617 $7K
84300 <1% 1,903 $7K
86663 <1% 552 $7K
80370 <1% 519 $7K
87425 <1% 641 $6K
86611 <1% 607 $6K
83519 <1% 799 $6K
80320 <1% 840 $6K
86701 <1% 810 $6K
80326 <1% 517 $6K
87220 <1% 1,858 $5K
82175 <1% 328 $5K
82435 <1% 1,778 $5K
85303 <1% 536 $5K
80353 <1% 748 $5K
80202 <1% 582 $5K
87254 <1% 569 $5K
83835 <1% 456 $5K
82575 <1% 891 $5K
83930 <1% 975 $5K
82374 <1% 1,483 $5K
86335 <1% 223 $5K
85384 <1% 604 $5K
83825 <1% 356 $4K
87906 <1% 55 $4K
80335 <1% 520 $4K
80162 <1% 765 $4K
87807 <1% 468 $4K
89055 <1% 1,088 $4K
80377 <1% 516 $4K
87185 <1% 1,120 $4K
80184 <1% 731 $4K
82166 <1% 183 $4K
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 5,834 $3K
80342 <1% 273 $3K
87631 <1% 40 $3K
82157 <1% 158 $3K
80299 <1% 245 $3K
80363 <1% 214 $3K
82787 <1% 203 $3K
85300 <1% 284 $3K
80357 <1% 555 $3K
82340 <1% 606 $3K
80339 <1% 215 $3K
86905 <1% 618 $3K
86000 <1% 914 $2K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed <1% 20 $2K
82239 <1% 110 $2K
87272 <1% 179 $2K
82104 <1% 194 $2K
87506 <1% 16 $2K
36416 <1% 2,667 $1K
85598 <1% 118 $1K
87109 <1% 187 $1K
80329 <1% 214 $1K
82553 <1% 139 $1K
88341 <1% 13 $1K
87641 <1% 42 $1K
81291 <1% 28 $1K
86774 <1% 119 $985.86
83625 <1% 126 $944.71
87535 <1% 41 $929.94
87276 <1% 84 $883.42
87275 <1% 84 $871.66
G0306 Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count <1% 313 $810.53
84255 <1% 54 $808.16
84133 <1% 287 $778.02
87207 <1% 158 $723.99
87999 <1% 199 $683.01
81270 <1% 13 $652.29
87484 <1% 30 $636.96
87468 <1% 26 $553.18
86671 <1% 56 $549.15
85597 <1% 45 $540.28
80330 <1% 116 $507.01
86684 <1% 57 $495.23
84163 <1% 59 $487.34
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) <1% 1,533 $485.06
80165 <1% 53 $415.00
82384 <1% 29 $410.16
81256 <1% 12 $407.55
86738 <1% 12 $373.06
81000 <1% 174 $365.40
83605 <1% 51 $362.87
87581 <1% 17 $360.90
87469 <1% 15 $339.15
80158 <1% 28 $320.29
83003 <1% 25 $312.84
80364 <1% 27 $278.63
84080 <1% 27 $268.17
80340 <1% 27 $267.24
80367 <1% 27 $258.73
87015 <1% 49 $249.29
80344 <1% 27 $245.22
86648 <1% 31 $234.80
86343 <1% 26 $222.86
87210 <1% 68 $207.70
80195 <1% 31 $205.31
80333 <1% 27 $199.46
82180 <1% 34 $179.45
82507 <1% 12 $176.28
86041 <1% 13 $153.71
86256 <1% 18 $142.54
G0475 Hiv antigen/antibody, combination assay, screening <1% 474 $107.00
83945 <1% 12 $101.98
86161 <1% 13 $85.49
G0328 Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous <1% 43 $69.94
84560 <1% 24 $55.56
81002 <1% 16 $32.13
96150 0% 1,444 $0.00
P9604 Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge 0% 91 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialTIMMERMAN, LEAH (VICE PRESIDENT)
Parent organizationQUEST DIAGNOSTICS INCORPORATED
Same official

Other billing entities under TIMMERMAN, LEAH

Full network →
ProviderLocationPaid
Unilab CorporationWest Hills, CA$668.50M
Quest Diagnostics IncorporatedClifton, NJ$637.74M
Quest Diagnostics LLC IlWood Dale, IL$429.84M
Quest Diagnostics Clinical Laboratories INCIrving, TX$276.76M
Quest Diagnostics Clinical Laboratories INCTucker, GA$211.13M
Quest Diagnostics Clinical Laboratories INCMiramar, FL$197.58M
Labone of Ohio INCCincinnati, OH$167.17M
Unilab CorporationSacramento, CA$141.24M
Quest Diagnostics Incorporated MDBaltimore, MD$121.81M
Quest Diagnostics IncorporatedLas Vegas, NV$59.32M
Quest Diagnostics LLC IlSchaumburg, IL$50.71M
Quest Diagnostics Clinical Laboratories INCTampa, FL$49.99M
Quest Diagnostics Nichols Institute, INC.Chantilly, VA$46.91M
Quest Diagnostics Nichols InstituteSan Juan Capistrano, CA$39.93M
Quest Diagnostics Clinical Laboratories INCNorristown, PA$22.72M
Specialty Laboratories INCWest Hills, CA$16.76M
Quest Diagnostics Clinical Laboratories INCDenver, CO$14.27M
Quest Diagnostics Clinical Laboratories INCHouston, TX$8.76M
Med Fusion, LLCLewisville, TX$4.17M
Quest Diagnostics Clinical Laboratories INCMaryland Heights, MO$2.98M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.